Results 171 to 180 of about 39,643 (228)

[Intradermal penile melanocytic tumor with complete resection in an adolescent: Clinical case]. [PDF]

Rev Med Inst Mex Seguro Soc
García-Lino JC, González AP, González-Cortés LF, Cano-Rodríguez MT, Corona-Jiménez JV, Paque-Bautista C, Sosa-Bustamante GP, Pascual-Jiménez D, Hernández-Robles CM, Vidaurri de la Cruz H, Murguía Pérez M.   +10 more
europepmc   +1 more source

Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers. [PDF]

NPJ Precis Oncol
Voulgarelis D, Forment JV, Herencia Ropero A, Polychronopoulos D, Cohen-Setton J, Bender A, Serra V, O'Connor MJ, Yates JWT, Bulusu KC.   +9 more
europepmc   +1 more source

[Coffin-Lowry syndrome: Case report in Mexico]. [PDF]

Rev Med Inst Mex Seguro Soc
Pérez-Peña AK, Juárez-Melchor D, Hernández-Castañeda Y.   +2 more
europepmc   +1 more source

[Herencia morbosa]

, 1881
openaire   +1 more source

Pregnancy Care Utilization, Experiences, and Outcomes Among Undocumented Immigrants in the United States: A Scoping Review. [PDF]

Womens Health Issues
Molina RL, Beecroft A, Pazos Herencia Y, Bazan M, Wade C, DiMeo A, Sprankle J, Sullivan MM.   +7 more
europepmc   +1 more source

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors. [PDF]

Front Oncol
Ayoub MM, Osman SA, Alkarbi RM, Anjum R, Malki A.   +4 more
europepmc   +1 more source

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

Cell Rep
Giuntini F, González-Larreategui Í, Herencia-Ropero A, Casacuberta-Serra S, Zacarías-Fluck MF, Arnal M, Pedretti F, Martínez-Martín S, Thabussot H, Cano VC, Grueso J, Foradada L, Serrano E, López-Estévez S, Rodriguez O, Guzman M, Rodriguez-Hernandez A, Brasó-Maristany F, Llop-Guevara A, Balmaña J, Nonell L, Prat A, Serra V, Beaulieu ME, Whitfield JR, Massó-Vallés D, Soucek L.   +26 more
europepmc   +1 more source